Drug intelligence / Profile preview

coenzyme q10 + lisinopril

Development stage
Unknown
Lead developer
Merck
Modality
Small Molecules
Administration
Oral
01

Overview

Coenzyme q10 + lisinopril is a combination of two agents with distinct mechanisms of action. Coenzyme Q10 (ubiquinone) is a naturally occurring antioxidant and essential component in mitochondrial electron transport, supporting cellular energy production and protecting cells from oxidative damage. It has been studied for its potential cardioprotective effects, particularly in the context of reducing cell damage after surgery or chemotherapy and possibly supporting heart health[4][2]. Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor used primarily to treat hypertension, heart failure, and certain kidney conditions by inhibiting the conversion of angiotensin I to angiotensin II, leading to vasodilation and reduced blood pressure[5][10]. The combination may be considered for additive cardiovascular protection or blood pressure management; however, evidence for combined use is limited mainly to preclinical studies or theoretical benefit[2]. Both agents are available individually; there are no widely recognized fixed-dose combination products containing both.

Other names
coq10 + lisinoprilubiquinone + lisinopril
02

Targets

bc1 complex (Cytochrome bc1 complex (plasmodium))ACE (Angiotensin Converting Enzyme)

Beyond the preview

Go deeper on coenzyme q10 + lisinopril.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on coenzyme q10 + lisinopril.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call